Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells
- PMID: 25052212
- PMCID: PMC4168798
- DOI: 10.1021/cb500340w
Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells
Abstract
Mcl-1 is overexpressed in many cancers and can confer resistance to cell-death signaling in refractory disease. Molecules that specifically inhibit Mcl-1 hold potential for diagnosing and disrupting Mcl-1-dependent cell survival. We selected three peptides from a yeast-surface display library that showed moderate specificity and affinity for binding to Mcl-1 over Bfl-1, Bcl-xL, Bcl-2, and Bcl-w. Specificity for Mcl-1 was improved by introducing threonine at peptide position 2e. The most specific peptide, MS1, bound Mcl-1 with 40-fold or greater specificity over four other human Bcl-2 paralogs. In BH3 profiling assays, MS1 caused depolarization in several human Mcl-1-dependent cell lines with EC50 values of ∼3 μM, contrasted with EC50 values of >100 μM for Bcl-2-, Bcl-xL-, or Bfl-1-dependent cell lines. MS1 is at least 30-fold more potent in this assay than the previously used Mcl-1 targeting reagent NoxaA BH3. These peptides can be used to detect Mcl-1 dependency in cells and provide leads for developing Mcl-1 targeting therapeutics.
Figures
Similar articles
-
Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.Cell Death Differ. 2015 Dec;22(12):2098-106. doi: 10.1038/cdd.2015.73. Epub 2015 Jun 5. Cell Death Differ. 2015. PMID: 26045046 Free PMC article.
-
Binding affinity of pro-apoptotic BH3 peptides for the anti-apoptotic Mcl-1 and A1 proteins: Molecular dynamics simulations of Mcl-1 and A1 in complex with six different BH3 peptides.J Mol Graph Model. 2017 May;73:115-128. doi: 10.1016/j.jmgm.2016.12.006. Epub 2017 Feb 9. J Mol Graph Model. 2017. PMID: 28279820
-
In silico and in vitro elucidation of BH3 binding specificity toward Bcl-2.Biochemistry. 2012 Jul 24;51(29):5841-50. doi: 10.1021/bi3003567. Epub 2012 Jul 12. Biochemistry. 2012. PMID: 22702834 Free PMC article.
-
Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1.ChemMedChem. 2016 Apr 19;11(8):802-13. doi: 10.1002/cmdc.201500497. Epub 2015 Dec 23. ChemMedChem. 2016. PMID: 26696548 Free PMC article. Review.
-
Targeting Mcl-1 for the therapy of cancer.Expert Opin Investig Drugs. 2011 Oct;20(10):1397-411. doi: 10.1517/13543784.2011.609167. Epub 2011 Aug 19. Expert Opin Investig Drugs. 2011. PMID: 21851287 Free PMC article. Review.
Cited by
-
Tertiary Structural Motif Sequence Statistics Enable Facile Prediction and Design of Peptides that Bind Anti-apoptotic Bfl-1 and Mcl-1.Structure. 2019 Apr 2;27(4):606-617.e5. doi: 10.1016/j.str.2019.01.008. Epub 2019 Feb 14. Structure. 2019. PMID: 30773399 Free PMC article.
-
ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors.Cancer Res. 2018 Feb 15;78(4):1044-1057. doi: 10.1158/0008-5472.CAN-17-1904. Epub 2017 Dec 19. Cancer Res. 2018. PMID: 29259014 Free PMC article.
-
Locating Herpesvirus Bcl-2 Homologs in the Specificity Landscape of Anti-Apoptotic Bcl-2 Proteins.J Mol Biol. 2015 Jul 31;427(15):2468-2490. doi: 10.1016/j.jmb.2015.05.015. Epub 2015 May 23. J Mol Biol. 2015. PMID: 26009469 Free PMC article.
-
Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.Cell Death Differ. 2015 Dec;22(12):2098-106. doi: 10.1038/cdd.2015.73. Epub 2015 Jun 5. Cell Death Differ. 2015. PMID: 26045046 Free PMC article.
-
Predicted Hotspot Residues Involved in Allosteric Signal Transmission in Pro-Apoptotic Peptide-Mcl1 Complexes.Biomolecules. 2020 Jul 28;10(8):1114. doi: 10.3390/biom10081114. Biomolecules. 2020. PMID: 32731448 Free PMC article.
References
-
- Beroukhim R.; Mermel C. H.; Porter D.; Wei G.; Raychaudhuri S.; Donovan J.; Barretina J.; Boehm J. S.; Dobson J.; Urashima M.; Mc Henry K. T.; Pinchback R. M.; Ligon A. H.; Cho Y.-J.; Haery L.; Greulich H.; Reich M.; Winckler W.; Lawrence M. S.; Weir B. A.; Tanaka K. E.; Chiang D. Y.; Bass A. J.; Loo A.; Hoffman C.; Prensner J.; Liefeld T.; Gao Q.; Yecies D.; Signoretti S.; Maher E.; Kaye F. J.; Sasaki H.; Tepper J. E.; Fletcher J. A.; Tabernero J.; Baselga J.; Tsao M.-S.; Demichelis F.; Rubin M. A.; Janne P. A.; Daly M. J.; Nucera C.; Levine R. L.; Ebert B. L.; Gabriel S.; Rustgi A. K.; Antonescu C. R.; Ladanyi M.; Letai A.; Garraway L. A.; Loda M.; Beer D. G.; True L. D.; Okamoto A.; Pomeroy S. L.; Singer S.; Golub T. R.; Lander E. S.; Getz G.; Sellers W. R.; Meyerson M. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905. - PMC - PubMed
-
- Wertz I. E.; Kusam S.; Lam C.; Okamoto T.; Sandoval W.; Anderson D. J.; Helgason E.; Ernst J. A.; Eby M.; Liu J.; Belmont L. D.; Kaminker J. S.; O’Rourke K. M.; Pujara K.; Kohli P. B.; Johnson A. R.; Chiu M. L.; Lill J. R.; Jackson P. K.; Fairbrother W. J.; Seshagiri S.; Ludlam M. J. C.; Leong K. G.; Dueber E. C.; Maecker H.; Huang D. C. S.; Dixit V. M. (2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471, 110–114. - PubMed
-
- Wei S.-H.; Dong K.; Lin F.; Wang X.; Li B.; Shen J.-J.; Zhang Q.; Wang R.; Zhang H.-Z. (2008) Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother. Pharmacol. 62, 1055–1064. - PubMed
-
- Letai A.; Bassik M. C.; Walensky L. D.; Sorcinelli M. D.; Weiler S.; Korsmeyer S. J. (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183–192. - PubMed
-
- Roberts A. W.; Seymour J. F.; Brown J. R.; Wierda W. G.; Kipps T. J.; Khaw S. L.; Carney D. A.; He S. Z.; Huang D. C. S.; Xiong H.; Cui Y.; Busman T. A.; McKeegan E. M.; Krivoshik A. P.; Enschede S. H.; Humerickhouse R. (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 30, 488–496. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
